Semax dosage

Protocol

1. 1

   Measure the dose

   Typical Semax dose is 0.6 mg (Intranasal cognitive use: 200 to 600 mcg/day in 2 to 3 divided doses. Stroke-recovery protocols (Russia): up to 18 mg/day intravenously in acute care.). Use a weight-based calculator for individual adjustments.

   Open tool →
2. 2

   Set the frequency

   Administer 2-3x daily (intranasal). Half-life of 0.5 hours anchors the dosing interval.

   Open tool →
3. 3

   Cycle if needed

   Russian cognitive protocols run 10 to 14 days. Acute stroke protocols are 5 to 10 days inpatient.

   Open tool →
4. 4

   Monitor for side effects

   Watch for: mild nasal irritation; transient mild headache; rare mild euphoria or activation. Stop or reduce dose if tolerability breaks down.

Why this dose

Modulates BDNF and NGF expression in hippocampus and cortex, enhances dopaminergic and serotonergic signaling, and reduces oxidative stress markers in preclinical ischemia models. Lacks corticotropic activity of native ACTH.

The typical dose (0.6 mg) reflects Intranasal cognitive use: 200 to 600 mcg/day in 2 to 3 divided doses. Stroke-recovery protocols (Russia): up to 18 mg/day intravenously in acute care.. Individual response varies with body weight, baseline status, concurrent training, and concurrent medications, so the labeled range is the starting point rather than the prescription.

How to administer

Semax is administered via the intranasal route. Intranasal delivery uses a metered spray; tilt the head slightly forward and breathe gently while spraying.

Onset of action runs around 30 minutes after administration. Peak effect lands near 2 hours post-dose. Plan the administration window so that peak effect lines up with whatever outcome you are dosing for, whether that is training, sleep, or symptom coverage.

Half-life note: Plasma half-life ~30 minutes. Behavioral and EEG effects persist for 6 to 24 hours after a single intranasal dose, indicating downstream signaling persistence.

Cycling and tolerance

Russian cognitive protocols run 10 to 14 days. Acute stroke protocols are 5 to 10 days inpatient.

The cycling rationale for receptor-active compounds is partly empirical and partly mechanistic: continuous high-dose stimulation can downregulate target receptors or accelerate negative-feedback loops on endogenous production. Built-in off-periods give the system time to resensitize before the next phase, which preserves the effective dose-response over a longer arc.

Effects to expect at typical dose

• Synthetic heptapeptide analog of ACTH(4-10) developed in Russia in the 1980s
• Approved in Russia for ischemic stroke, cognitive impairment, and cerebrovascular disorders
• Lacks the corticotropic activity of native ACTH due to the Pro-Gly-Pro stabilizing tail
• Russian RCTs report improved cognitive recovery in acute ischemic stroke versus standard care
• Modulates BDNF and NGF expression and dopaminergic signaling in preclinical models
• Standard route is intranasal; not FDA approved; research-use-only outside Russia

Side effects and interactions

Common side effects

• mild nasal irritation
• transient mild headache
• rare mild euphoria or activation

Notable interactions

• stimulants (caffeine, amphetamines) (minor): potential additive activation; monitor for overstimulation
• antipsychotics (minor): theoretical antagonism via dopaminergic modulation

Lists above cover commonly reported and well-characterized items. They are not exhaustive: review the full Semax profile and discuss with a clinician familiar with your medication list before starting, particularly if you are on prescription therapy or have a chronic condition.

Regulatory snapshot

WADA status

unknown

DEA / Rx

Not FDA approved; not scheduled; research-chemical status outside Russia

Pregnancy

Not recommended; insufficient data

Legal status

Approved in Russia for stroke and cognitive disorders; not FDA approved; research-use-only grey market elsewhere

Do not use if

• pregnancy
• lactation
• acute psychotic disorder
• severe hypertension (caution due to mild activating effect)

Related research